Guardant Health’s recent $292 million victory against Natera in a false advertising lawsuit sets a critical precedent for the biotech industry, highlighting the severe consequences of misleading claims. This case is a wake-up call for drug and device companies navigating complex FDA and FTC regulations. False advertising not only misleads stakeholders but also exposes companies to significant financial losses and regulatory scrutiny.

Compliance officers and marketers must work together to ensure promotional materials are accurate, legally sound, and fully substantiated. Your PRC team should include both regulatory experts and legal professionals to verify claims, substantiate benefits, and avoid exaggerations. The cost of non-compliance can far exceed the effort required to get it right.

At Kulkarni Law Firm, we help companies mitigate advertising risks and stay compliant. Subscribe to our podcast for practical insights, and contact us to safeguard your organization’s reputation and bottom line. What steps has your company taken to audit its advertising practices? Share your thoughts with us!

Support the show